ABSTRACT
As a zoonotic pathogen, Streptococcus suis(S. suis) takes pigs as the main host and is mainly colonizes in the upper respiratory tract and tonsil of pigs, causing septicemia, endocarditis and meningitis in pigs. Pyruvate dehydrogenase (PDH) is an enzyme that catalyzes the conversion of pyruvate to acetyl-CoA. As an immunogenic membrane-associated protein in S. suis, it has been found to be closely related to the formation of biofilm. In this study, the recombinant PDH (rPDH) of S. suis ZY05719 (serotype 2) was expressed and purified in E. coli by His affinity chromatography. Western blotting analysis showed that there was a strong specific reaction between PDH protein and PDH antiserum. Mice were immunized with recombinant PDH and inactivated bacteria, and the relative survival rates were 70 % and 60 %, respectively. In addition, mice immunized with PDH caused high levels of antibodies and high expression of immune-related genes in the spleen, which significantly protected the liver, brain and spleen from pathological damage. In addition, PDH antiserum could significantly inhibit the growth of S. suis and the formation of S. suis biofilm in vitro. These results further suggest that PDH is a promising candidate for S. suis biofilm-related subunit vaccine.
Subject(s)
Bacterial Proteins , Biofilms , Oxidoreductases , Recombinant Proteins , Streptococcal Infections , Streptococcus suis , Animals , Bacterial Proteins/genetics , Bacterial Proteins/immunology , Escherichia coli/genetics , Immunization/veterinary , Mice , Oxidoreductases/genetics , Oxidoreductases/immunology , Recombinant Proteins/genetics , Recombinant Proteins/immunology , Streptococcal Infections/prevention & control , Streptococcal Infections/veterinary , Streptococcus suis/genetics , Swine , Swine Diseases/prevention & control , Vaccine DevelopmentABSTRACT
OBJECTIVE: Gisenoside Rg1 is a potent neuroprotectant in ginseng. The aim of this study was to investigate the elimination effect of Rg1 on cadmium (Cd)-induced neurotoxicity. MATERIALS AND METHODS: A cumulative Cd exposure mouse model was established. Also, the toxicity of Cd and the protective effect of Rg1 were examined in vitro using cultured neurons and microglia. RESULTS: We found that Cd-intoxicated mice exhibited significant injury in the liver, kidney, small intestine, and testis, along with cognitive impairment. Antioxidant enzymes such as SOD, GSH-Px and CAT were reduced in the blood and brain, and correspondingly, the lipid peroxidation product MDA was elevated. In the brain, astrocytes and microglia were activated, characterized by an increase in inflammatory factors such as TNF-α, IL-1ß and IL-6, as well as their protein markers GFAP and IBA1. However, Rg1 eliminated Cd-induced toxicity and restored oxidative stress and inflammatory responses, correspondingly restoring the behavioral performance of the animals. Meanwhile, the BDNF-TrkB/Akt and Notch/HES-1 signaling axes were involved in the Rg1-mediated elimination of Cd-induced toxicity. CONCLUSION: Rg1 is a promising agent for the elimination of Cd-induced toxicity.
Subject(s)
Anti-Inflammatory Agents/therapeutic use , Cadmium , Ginsenosides/therapeutic use , Neuroprotective Agents/therapeutic use , Neurotoxicity Syndromes/drug therapy , Animals , Anti-Inflammatory Agents/pharmacology , Apoptosis/drug effects , Brain/drug effects , Brain/immunology , Brain/pathology , Cell Survival/drug effects , Cells, Cultured , Cytokines/genetics , Cytokines/immunology , Ginsenosides/pharmacology , Intestine, Small/drug effects , Intestine, Small/pathology , Kidney/drug effects , Kidney/pathology , Liver/drug effects , Liver/pathology , Male , Mice, Inbred C57BL , Microglia/drug effects , Microglia/pathology , Neurons/drug effects , Neurons/pathology , Neuroprotective Agents/pharmacology , Neurotoxicity Syndromes/immunology , Neurotoxicity Syndromes/pathology , Oxidative Stress/drug effects , Oxidoreductases/immunology , Testis/drug effects , Testis/pathologyABSTRACT
Animals acquire nutrients and energy through feeding to achieve a balance between growth and organismal health. When there is a change in nutrient acquisition, the state of growth changes and may also cause changes in the intrinsic immune system. Compensatory growth (CG), a specific growth phenomenon, involves the question of whether changes in growth can be accompanied by changes in innate immunity. The zebrafish (Danio rerio), a well-known fish model organism, can serve as a suitable model. In this study, the zebrafish underwent 3 weeks of fasting and refeeding for 3 to 7 day periods. It was found that CG could be achieved in zebrafish. Zebrafish susceptibility to Streptococcus agalactiae increased after starvation. In addition, the amount of melano-macrophage centers increased after fasting and the proportion of injured tubules increased after refeeding for 3 and 5 days, respectively. Furthermore, the kidneys of zebrafish suffering from starvation were under oxidative stress, and the activity of several antioxidant enzymes increased after starvation, including catalase, glutathione peroxidases and superoxide dismutase. Innate immune parameters were influenced by starvation. Additionally, the activity of alkaline phosphatase and lysozyme increased after starvation. The mRNA expression of immune-related genes like il-1ß was elevated to a different extent after fasting with or without lipopolysaccharides (LPS) challenge. This study showed that the function of the innate immune system in zebrafish could be influenced by nutrition status.
Subject(s)
Eating/immunology , Fasting , Immunity, Innate , Kidney/immunology , Zebrafish/immunology , Animals , Antioxidants , Interleukin-1beta/immunology , Lipopolysaccharides/toxicity , Oxidoreductases/immunology , Zebrafish Proteins/immunologyABSTRACT
The exact mechanisms of multiple sclerosis (MS) development are still unknown, but the development of experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice is associated with the violation of bone marrow hematopoietic stem cells (HSCs) differentiation profiles associated with the production of harmful for human's autoantibodies hydrolyzing myelin basic protein, myelin oligodendrocyte glycoprotein (MOG35-55), and DNA. It was shown that IgGs from the sera of healthy humans and autoimmune patients oxidize many different compounds due to their H2O2-dependent peroxidase and oxidoreductase activity in the absence of H2O2. Here we first analyzed the change in the relative redox activities of IgGs antibodies from the blood of C57BL/6 mice over time at different stages of the EAE development. It was shown that the peroxidase activity of mice IgGs in the oxidation of ABTS (2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) is on average 6.9-fold higher than the oxidoreductase activity. The peroxidase activity of IgGs increased during the spontaneous development of EAE during 40 days, 1.4-fold. After EAE development acceleration due to mice immunization with MOG35-55 (5.3-fold), complexes of bovine DNA with methylated bovine serum albumin (DNA-metBSA; 3.5-fold), or with histones (2.6-fold), the activity was increased much faster. The increase in peroxidase activity after mice immunization with MOG35-55 and DNA-metBSA up to 40 days of experiments was relatively gradual, while for DNA-histones complex was observed its sharp increase at the acute phase of EAE (14-20 days). All data show that IgGs' redox activities can play an important role in the protection of mice from toxic compounds and oxidative stress.
Subject(s)
Antibodies, Catalytic/metabolism , Autoantibodies/metabolism , Encephalomyelitis, Autoimmune, Experimental/enzymology , Hematopoietic Stem Cells/immunology , Oxidoreductases/metabolism , Peroxidases/metabolism , Animals , Cell Differentiation/drug effects , Cell Proliferation/drug effects , Encephalomyelitis, Autoimmune, Experimental/chemically induced , Encephalomyelitis, Autoimmune, Experimental/immunology , Encephalomyelitis, Autoimmune, Experimental/pathology , Hematopoietic Stem Cells/drug effects , Hematopoietic Stem Cells/pathology , Humans , Hydrogen Peroxide/pharmacology , Immunoglobulin G/metabolism , Mice , Mice, Inbred C57BL , Myelin Basic Protein/metabolism , Myelin-Oligodendrocyte Glycoprotein/administration & dosage , Oxidation-Reduction , Oxidoreductases/immunology , Peptide Fragments/administration & dosage , Peroxidases/immunologyABSTRACT
The biological and medicinal impacts of proteolysis-targeting chimeras (PROTACs) and related chimeric molecules that effect intracellular degradation of target proteins via ubiquitin ligase-mediated ubiquitination continue to grow. However, these chimeric entities are relatively large compounds that often possess molecular characteristics, which may compromise oral bioavailability, solubility, and/or in vivo pharmacokinetic properties. We therefore explored the conjugation of such molecules to monoclonal antibodies using technologies originally developed for cytotoxic payloads so as to provide alternate delivery options for these novel agents. In this report, we describe the first phase of our systematic development of antibody-drug conjugates (ADCs) derived from bromodomain-containing protein 4 (BRD4)-targeting chimeric degrader entities. We demonstrate the antigen-dependent delivery of the degrader payloads to PC3-S1 prostate cancer cells along with related impacts on MYC transcription and intracellular BRD4 levels. These experiments culminate with the identification of one degrader conjugate, which exhibits antigen-dependent antiproliferation effects in LNCaP prostate cancer cells.
Subject(s)
Cell Cycle Proteins/antagonists & inhibitors , Dipeptides/pharmacology , Heterocyclic Compounds, 3-Ring/pharmacology , Immunoconjugates/pharmacology , Proteolysis/drug effects , Transcription Factors/antagonists & inhibitors , Antibodies, Monoclonal/immunology , Antigens, Neoplasm/immunology , Cell Cycle Proteins/metabolism , Cell Proliferation/drug effects , Dipeptides/chemical synthesis , Dipeptides/pharmacokinetics , Heterocyclic Compounds, 3-Ring/chemical synthesis , Heterocyclic Compounds, 3-Ring/pharmacokinetics , Humans , Immunoconjugates/chemistry , Immunoconjugates/immunology , Oxidoreductases/immunology , PC-3 Cells , Transcription Factors/metabolism , Von Hippel-Lindau Tumor Suppressor Protein/metabolismABSTRACT
Heterobifunctional compounds that direct the ubiquitination of intracellular proteins in a targeted manner via co-opted ubiquitin ligases have enormous potential to transform the field of medicinal chemistry. These chimeric molecules, often termed proteolysis-targeting chimeras (PROTACs) in the chemical literature, enable the controlled degradation of specific proteins via their direction to the cellular proteasome. In this report, we describe the second phase of our research focused on exploring antibody-drug conjugates (ADCs), which incorporate BRD4-targeting chimeric degrader entities. We employ a new BRD4-binding fragment in the construction of the chimeric ADC payloads that is significantly more potent than the corresponding entity utilized in our initial studies. The resulting BRD4-degrader antibody conjugates exhibit potent and antigen-dependent BRD4 degradation and antiproliferation activities in cell-based experiments. Multiple ADCs bearing chimeric BRD4-degrader payloads also exhibit strong, antigen-dependent antitumor efficacy in mouse xenograft assessments that employ several different tumor models.
Subject(s)
Antineoplastic Agents/therapeutic use , Cell Cycle Proteins/antagonists & inhibitors , Cell Proliferation/drug effects , Immunoconjugates/therapeutic use , Neoplasms/drug therapy , Proteolysis/drug effects , Transcription Factors/antagonists & inhibitors , Animals , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/pharmacokinetics , Antibodies, Monoclonal/therapeutic use , Antigens, Neoplasm/immunology , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/pharmacokinetics , Cell Cycle Proteins/metabolism , Cell Line, Tumor , Dipeptides/chemical synthesis , Dipeptides/pharmacokinetics , Dipeptides/therapeutic use , Female , Heterocyclic Compounds, 3-Ring/chemical synthesis , Heterocyclic Compounds, 3-Ring/pharmacokinetics , Heterocyclic Compounds, 3-Ring/therapeutic use , Humans , Immunoconjugates/immunology , Immunoconjugates/pharmacokinetics , Mice, SCID , Oxidoreductases/immunology , Transcription Factors/metabolism , Von Hippel-Lindau Tumor Suppressor Protein/metabolism , Xenograft Model Antitumor AssaysABSTRACT
Type 17 cytokines have been strongly implicated in mucosal immunity, in part by regulating the production of antimicrobial peptides. Using a mouse model of Citrobacter rodentium infection, which causes colitis, we found that intestinal IL-17RA and IL-17RC were partially required for control of infection in the colon and IL-17 regulates the production of luminal hydrogen peroxide as well as expression of Tnsf13 Reduced Tnfsf13 expression was associated with a profound defect in generating C. rodentium-specific IgA+ Ab-secreting cells. Taken together, intestinal IL-17R signaling plays key roles in controlling invading pathogens, in part by regulating luminal hydrogen peroxide as well as regulating the generation of pathogen-specific IgA+ Ab-secreting cells.
Subject(s)
Citrobacter rodentium/immunology , Enterobacteriaceae Infections/immunology , Immunoglobulin A, Secretory/immunology , Intestinal Mucosa/immunology , Oxidoreductases/immunology , Receptors, Interleukin-17/immunology , Signal Transduction/immunology , Animals , Disease Models, Animal , Enterobacteriaceae Infections/genetics , Humans , Hydrogen Peroxide/immunology , Immunoglobulin A, Secretory/genetics , Mice , Mice, Knockout , Oxidoreductases/genetics , Receptors, Interleukin-17/genetics , Signal Transduction/geneticsABSTRACT
As a prevalent autoimmune disease of the central nervous system in young adults, multiple sclerosis (MS) is mediated by T cells, particularly CD4+ subsets. Given the evidence that the perturbation in reactive oxygen species (ROS) production has a pivotal role in the onset and progression of MS, its regulation through the antioxidant molecules is too important. Here, we investigated the level of the redox system components in lymphocytes and CD4+ T cells of MS patients. The study was performed on relapsing-remitting MS (RRMS) patients (n = 29) and age- and sex-matched healthy controls (n = 15). Peripheral blood mononuclear cells (PBMCs) were cultured and stimulated by anti-CD3/CD28. The level of ROS, anion superoxide (O2 -), and L-ð¾-glutamyl-Lcysteinylglycine (GSH) was measured by flow cytometry in lymphocytes/CD4+ T cells. The gene expression level of gp91phox, catalase, superoxide dismutase 1/2 (SOD), and nuclear factor-E2-related factor (Nrf2) was also measured by real-time PCR. We found that lymphocytes/CD4+ T cells of RRMS patients at the relapse phase significantly produced higher levels of ROS and O2 - compared to patients at the remission phase (P value < 0.001) and healthy controls (P value < 0.001 and P value < 0.05, respectively). Interestingly, the gene expression level of gp91phox, known as the catalytic subunit of the NADPH oxidase, significantly increased in MS patients at the relapse phase (P value < 0.05). Furthermore, the catalase expression augmented in patients at the acute phase (P value < 0.05), while an increased expression of SOD1 and Nrf2 was found in RRMS patients at relapse and remission phases (P value < 0.05). The increased production of ROS in CD4+ T cells of RRMS patients highlights the importance of amplifying antioxidant components as an efficient approach to ameliorate disease activity in MS patients.
Subject(s)
CD4-Positive T-Lymphocytes/immunology , Gene Expression Regulation/immunology , Multiple Sclerosis/immunology , NF-E2-Related Factor 2/immunology , Oxidoreductases/immunology , Superoxides/immunology , Adult , CD4-Positive T-Lymphocytes/pathology , Female , Humans , Male , Multiple Sclerosis/pathology , Oxidation-Reduction , RecurrenceABSTRACT
Selenium (Se) has been recognized as an essential dietary nutrient for decades, and organic Se sources rather than inorganic ones are increasingly advocated as Se supplements. Earthworms have been studied as a feed additive and animal protein source for many yr. The aim of this study was to evaluate the effect of Se-enriched earthworm powder (SEP) on the antioxidative ability and immunity of laying hens. A total of 120 27-wk-old laying hens were randomly divided into 4 groups (30 hens per group). Laying hens were fed diets supplemented with SEP having 0, 0.5, or 1 mg/kg of Se or with earthworm powder alone. After 5 wk of supplementation, serum from the hens was tested for nutritional components (protein, globulin, albumin, triglycerides, total cholesterol, and glucose), antioxidative properties (glutathione peroxidase, superoxide dismutase, catalase, and nitric oxide), and immune responses (lysozymes, immunoglobulin G, IL-2, and interferon gamma). We found that SEP with 1.0 mg/kg of Se upregulated the hens' total protein, albumin, glutathione peroxidase, superoxide dismutase, IgG, and IL-2 and downregulated triglycerides, total cholesterol, glucose, and nitric oxide. These results indicate that SEP improves antioxidative levels and immune function of laying hens, indicating potential benefit from use of SEP as a feed additive in the poultry industry.
Subject(s)
Dietary Supplements , Immunity , Oligochaeta , Selenium , Animal Feed/analysis , Animal Nutritional Physiological Phenomena , Animals , Chickens , Diet/veterinary , Female , Immunity/drug effects , Oligochaeta/chemistry , Oxidoreductases/immunology , Powders , Selenium/pharmacologyABSTRACT
This study investigated the stimulatory effects of dietary inclusion of Gracilariopsis persica (GP), Hypnea flagelliformis (HF) and Sargassum boveanum (SB) on immune indices, antioxidant capability and immune related genes expression of rainbow trout (Oncorhynchus mykiss). Seven iso-nitrogenous and iso-caloric diets with 0, 5 and 10% of each macroalgae were prepared and fed to rainbow trout juveniles for 83 days. Serum lysozyme (Lyz) and respiratory burst activity (NBT) along with activity of superoxide dismutase (SOD), peroxidase (POD) and catalase (CAT) and expression of LyzII, TNFα and IL-1ß genes in head kidney samples were determined by days 47 and 83. Our results revealed that dietary inclusion of seaweeds improved fish immune status. Long term feeding of fish on seaweed contained diets (except for GP10) improved serum Lyz activity in comparison to control group. Similarly, extended feeding on GP5 and HF10 and HF10 included diets improved SOD and POD levels, respectively. Genes expression studies revealed that seaweeds contained diets noticeably enhanced expression of LyzII, TNFα and IL-1ß in comparison to control fish. However, results revealed that such stimulatory effects were more evident at lower dietary inclusion level and shorter feeding time. In conclusion, the results depicted that dietary inclusion of the seaweeds effectively improved serum immune indices and head kidney antioxidant status and immune related genes expression in a time and dose dependent manner.
Subject(s)
Oncorhynchus mykiss/immunology , Rhodophyta , Sargassum , Seaweed , Animals , Catalase/immunology , Diet/veterinary , Fish Proteins/genetics , Fish Proteins/immunology , Head Kidney/immunology , Immunomodulation , Interleukin-1beta/genetics , Muramidase/blood , Muramidase/genetics , Oncorhynchus mykiss/genetics , Oxidoreductases/immunology , Superoxide Dismutase/immunology , Tumor Necrosis Factor-alpha/genetics , Up-RegulationABSTRACT
BACKGROUND: Tuberculosis (TB) caused by Mycobacterium tuberculosis (MTB), especially the drug-resistant MTB, poses serious challenges to human healthcare worldwide. Cytotoxic T lymphocytes (CTLs) play a vital role in immune defense against MTB. OBJECTIVE: To identify novel CTL epitopes that could induce cellular immunity against MTB infections. METHODS: The HLA-A*0201 restricted CTL epitopes of the drug-resistant protein InhA from MTB were predicted by online algorisms and synthesized by the Fmoc solid phase method. The candidate peptides were used to induce CTLs from human peripheral blood mononuclear cells (PBMCs) of HLA-A*0201 healthy donors and the HLA-2.1/Kb mice. IFN-γ productions of CTLs were detected by enzyme linked immunospot assay (ELISPOT), flow cytometry and enzyme-linked immunosorbent assay (ELISA), and cytotoxicity was analyzed by lactate dehydrogenase (LDH) assay. RESULTS: A group of 4 epitopes were screened out with high affinities to HLA-A*0201. ELISPOT and flow cytometry analysis indicated these peptides significantly induced that IFN-γ release of CTLs from the HLA-A*0201+/PPD+ donors, as the mutant analogues had more potent stimulation effects. LDH assay showed that CTLs from PPD+ donors and the immunized mice exhibited significant cytotoxicity and low cross-reactivity. ELISA analysis revealed comparative levels of IFN-γ were released by CTLs isolated from the mice spleen. CONCLUSION: Our study has identified 4 novel CTL epitopes of InhA that could elicit potent CTL immunity, establishing a foundation for the development of multivalent peptide vaccines against the drug-resistant MTB.
Subject(s)
Bacterial Proteins/immunology , Drug Resistance, Bacterial/immunology , Epitopes, T-Lymphocyte/immunology , Immunity, Cellular , Mycobacterium tuberculosis/immunology , Oxidoreductases/immunology , T-Lymphocytes, Cytotoxic/immunology , Animals , Bacterial Proteins/genetics , Drug Resistance, Bacterial/genetics , Epitopes, T-Lymphocyte/genetics , HLA-A2 Antigen/genetics , HLA-A2 Antigen/immunology , Humans , Mice , Mice, Transgenic , Mycobacterium tuberculosis/genetics , Oxidoreductases/geneticsABSTRACT
While immune checkpoint inhibition is rapidly becoming standard of care in many solid tumors, immune checkpoint inhibitors (ICIs) fail to induce clinical responses in many patients, presumably due to insufficient numbers of tumor-specific T cells in the tumor milieu. To this end, immunization protocols using viral vectors expressing tumor-associated antigens are being explored to induce T cell responses that synergize with ICIs. However, the optimal combination of vaccine and immune checkpoint regimen remains undefined. Here, a dendritic cell-targeting lentiviral vector (ZVex®) expressing the endogenous murine tyrosinase-related protein 1 (mTRP1), or the human tumor antigen NY-ESO-1, was explored as monotherapy or heterologous prime-boost (HPB) vaccine regimen together with recombinant tumor antigen in the murine B16 melanoma model. PD1/PDL1 blockade significantly enhanced ZVex/mTRP1, but not ZVex/NY-ESO-1, induced immune responses in mice, whereas the opposite effect was observed with anti-CTLA4 antibody. Anti-tumor efficacy of anti-PD1, but not anti-PDL1 or anti-CTLA4, was significantly enhanced by ZVex/mTRP1 and HPB vaccination. These results suggest mechanistic differences in the effect of checkpoint blockade on vaccine-induced immune and anti-tumor responses against self versus non-self tumor antigens, possibly due to tolerance and state of exhaustion of anti-tumor T cells.
Subject(s)
Antigens, Neoplasm/immunology , Cancer Vaccines/immunology , Dendritic Cells/immunology , Immune Checkpoint Inhibitors/pharmacology , Melanoma, Experimental , Membrane Glycoproteins/immunology , Membrane Proteins/immunology , Oxidoreductases/immunology , Animals , B7-H1 Antigen/antagonists & inhibitors , Genetic Vectors , Humans , Lentivirus , Melanoma, Experimental/therapy , Mice , Programmed Cell Death 1 Receptor/antagonists & inhibitorsABSTRACT
Six-transmembrane epithelial antigen of prostate-1 (STEAP1) is a relatively newly identified target in prostate cancer. We evaluated the ability of PET/CT with 89Zr-DFO-MSTP2109A, an antibody that recognizes STEAP1, to detect lesions in patients with metastatic castration-resistant prostate cancer (mCRPC). Methods: Nineteen mCRPC patients were prospectively imaged using approximately 185 MBq/10 mg of 89Zr-DFO-MSTP2109A. 89Zr-DFO-MSTP2109A PET/CT images obtained 4-7 d after injection were compared with bone and CT scans. Uptake in lesions was measured. Fifteen patients were treated with an antibody-drug conjugate (ADC) based on MSTP2109A; ADC treatment-related data were correlated with tumor uptake by PET imaging. Bone or soft-tissue biopsy samples were evaluated. Results: No significant toxicity occurred. Excellent uptake was observed in bone and soft-tissue disease. Median SUVmax was 20.6 in bone and 16.8 in soft tissue. Sixteen of 17 lesions biopsied were positive on 89Zr-DFO-MSTP2109A, and all sites were histologically positive (1 on repeat biopsy). Bayesian analysis resulted in a best estimate of 86% of histologically positive lesions being true-positive on imaging (95% confidence interval, 75%-100%). There was no correlation between SUVmax tumor uptake and STEAP1 immunohistochemistry, survival after ADC treatment, number of ADC treatment cycles, or change in prostate-specific antigen level. Conclusion:89Zr-DFO-MSTP2109A is well tolerated and shows localization in mCRPC sites in bone and soft tissue. Given the high SUV in tumor and localization of a large number of lesions, this reagent warrants further exploration as a companion diagnostic in patients undergoing STEAP1-directed therapy.
Subject(s)
Antigens, Neoplasm/immunology , Immunoconjugates/immunology , Oxidoreductases/immunology , Positron Emission Tomography Computed Tomography/methods , Prostatic Neoplasms, Castration-Resistant/diagnostic imaging , Prostatic Neoplasms, Castration-Resistant/pathology , Radioisotopes , Zirconium , Aged , Aged, 80 and over , Humans , Immunoconjugates/pharmacokinetics , Male , Middle Aged , Neoplasm Metastasis , Radiometry , Tissue DistributionABSTRACT
A six-transmembrane epithelial antigen of prostate-1 (STEAP1) is a newly identified target in prostate cancer. The use of radio-labeled STEAP1-targeting antibodies with positron emission tomography (PET) may allow for detection of sites of metastatic prostate cancer and may refine patient selection for antigen-directed therapies. This was a prospective study in seven patients with metastatic castration-resistant prostate cancer who had at least one archival biopsy that was STEAP1-positive by immunohistochemistry. Patients received intravenous injections of â¼185 MBq and 10 mg of [89Zr]Zr-DFO-MSTP2109A, a humanized IgG1 monoclonal antibody directed against STEAP1. PET/CT images, blood samples, and whole-body counts were monitored longitudinally in six patients. Here, we report on safety, biodistribution, pharmacokinetics, dose estimates to normal tissues, and initial tumor targeting for this group of patients. There was no significant acute or subacute toxicity. Favorable biodistribution and enhanced lesion uptake (in both bone and soft tissue) were observed on imaging using a mass of 10 mg of DFO-MSTP2109A. The best lesion discrimination was seen at the latest imaging time, a median of 6 days postadministration. Pharmacokinetics showed a median serum T1/2 ß of 198 h, volume of central compartment of 3.54 L (similar to plasma volume), and clearance of 19.7 mL/h. The median biologic T1/2 for whole-body retention was 469 h. The highest mean absorbed doses to normal organs (mGy/MBq) were 1.18, 1.11, 0.78, 0.73, and 0.71 for liver, heart wall, lung, kidney, and spleen, respectively. Excellent targeting of metastatic prostate sites in both bone and soft tissue was observed, with an optimal imaging time of 6 days postadministration. The liver and heart were the normal organs that experienced the highest absorbed doses. The pharmacokinetics were similar to other antibodies without major cross-reactivity with normal tissues. A more detailed analysis of lesion targeting in a larger patient population with correlation to immunohistology and standard imaging modalities has been reported.
Subject(s)
Antibodies, Monoclonal, Humanized/pharmacokinetics , Antigens, Neoplasm/immunology , Bone Neoplasms/diagnostic imaging , Bone Neoplasms/secondary , Oxidoreductases/immunology , Prostatic Neoplasms, Castration-Resistant/diagnostic imaging , Radioisotopes/pharmacokinetics , Radiopharmaceuticals/pharmacokinetics , Soft Tissue Neoplasms/diagnostic imaging , Soft Tissue Neoplasms/secondary , Zirconium/pharmacokinetics , Antibodies, Monoclonal, Humanized/administration & dosage , Antibodies, Monoclonal, Humanized/therapeutic use , Cross Reactions/immunology , Humans , Immunoglobulin G/administration & dosage , Immunoglobulin G/metabolism , Immunoglobulin G/therapeutic use , Inhibitory Concentration 50 , Injections, Intravenous , Male , Positron Emission Tomography Computed Tomography/methods , Prospective Studies , Prostatic Neoplasms, Castration-Resistant/blood , Prostatic Neoplasms, Castration-Resistant/drug therapy , Radioisotopes/administration & dosage , Radiopharmaceuticals/administration & dosage , Tissue Distribution , Zirconium/administration & dosageABSTRACT
In order to define the role of oxalic acid (OA) in the invasion of Botrytis cinerea in tomato plants, the OA induction of resistance related to oxalate oxidase (O×O) and germin was examined. In greenhouse experiments, OA at 3 mmol/L significantly induced resistance in tomato plants against B. cinerea strains B05.10 and T4, reducing lesion size of 37.55% and 24.91% by compared with distilled water control, respectively, while 20 mmol/L OA increasing by 36.14% and 41.48%. OA contents were 98 and 46 µg/mL when tomato plants were infected by B. cinerea strains B05.10 and T4, respectively. To define the molecular-genetic mechanisms, we compared the gene expression under four different conditions: 3 mmol/L OA-treated plants, 20 mmol/L OA-treated plants, B. cinerea strain B05.10-infected plants (B05.10 Inf plants) and B. cinerea strain T4-infected plants (T4 Inf plants). In 3 mmol/L OA-treated plants, the expressions of O×O and Germin peaked at 48 h after spraying, with approximate threefold and 18-fold increase compared with the control expression, respectively. In T4 Inf plants, the expression (mRNA accumulation) of O×O and Germin reached the highest levels at 24 h after inoculation, with 3- and 13-times that immediately after inoculation, respectively. In total, these findings suggest that elevated levels of OA correlated with increased fungal invasion and lower OA induced resistance in tomato plants by increasing expressions of O×O and Germin.
Subject(s)
Botrytis/physiology , Oxalic Acid/immunology , Plant Diseases/microbiology , Solanum lycopersicum/immunology , Disease Resistance , Gene Expression Regulation, Plant , Solanum lycopersicum/genetics , Solanum lycopersicum/microbiology , Oxidoreductases/genetics , Oxidoreductases/immunology , Plant Diseases/genetics , Plant Diseases/immunology , Plant Proteins/genetics , Plant Proteins/immunologyABSTRACT
The recombinant murine IgG2a antibody TA99, directed against a melanoma antigen, was used to study combination modalities that potentiate antibody-dependent cell cytotoxicity. As previously reported, IgG2a(TA99) was extremely efficacious in preventing the growth of B16 lung metastases. However, the same antibody mediated only minimal tumor growth retardation when used to treat established neoplastic masses. The therapeutic activity of IgG2a(TA99) could be substantially enhanced by co-administration with an antibody-cytokine fusion (TA99-murine tumor necrosis factor [mTNF]), consisting of the TA99 antibody in single-chain variable fragment format fused to murine TNF. This fusion protein efficiently killed endothelial cells in vitro and displayed only minimal activity against B16 melanoma cells. In vivo, TA99-mTNF boosted the influx of natural killer cells and macrophages into B16 melanoma lesions. Therapy studies with two different administration schedules showed that the combination of TA99-mTNF and IgG2a(TA99) was superior to the individual products used as single agents. The combination treatment converted most of the tumor mass into a necrotic lesion, but a vital tumor rim eventually regrew, even when dacarbazine was included in the therapeutic regimen. The treatment modality described in this article may be applicable to the treatment of melanoma patients, given the specificity of the gp75 antigen and its conservation across species.
Subject(s)
Antigens, Neoplasm/immunology , Immunoconjugates/administration & dosage , Melanoma, Experimental/drug therapy , Membrane Glycoproteins/immunology , Oxidoreductases/immunology , Skin Neoplasms/drug therapy , Animals , Antibodies, Monoclonal, Murine-Derived/administration & dosage , Antibodies, Monoclonal, Murine-Derived/genetics , Antibodies, Monoclonal, Murine-Derived/isolation & purification , CHO Cells , Cell Line, Tumor/transplantation , Cricetulus , Drug Administration Schedule , Drug Screening Assays, Antitumor , Female , Humans , Immunoconjugates/genetics , Immunoconjugates/isolation & purification , Immunoglobulin G/immunology , Melanoma, Experimental/immunology , Melanoma, Experimental/pathology , Mice , Recombinant Fusion Proteins/administration & dosage , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/isolation & purification , Skin Neoplasms/immunology , Skin Neoplasms/pathology , Tumor Necrosis Factor-alpha/administration & dosage , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/isolation & purificationABSTRACT
Therapy with tumor-specific Abs is common in the clinic but has limited success against solid malignancies. We aimed at improving the efficacy of this therapy by combining a tumor-specific Ab with immune-activating compounds. In this study, we demonstrate in the aggressive B16F10 mouse melanoma model that concomitant application of the anti-TRP1 Ab (clone TA99) with TLR3-7/8 or -9 ligands, and IL-2 strongly enhanced tumor control in a therapeutic setting. Depletion of NK cells, macrophages, or CD8+ T cells all mitigated the therapeutic response, showing a coordinated immune rejection by innate and adaptive immune cells. FcγRs were essential for the therapeutic effect, with a dominant role for FcγRI and a minor role for FcγRIII and FcγRIV. FcγR expression on NK cells and granulocytes was dispensable, indicating that other tumoricidal functions of NK cells were involved and implicating that FcγRI, -III, and -IV exerted their activity on macrophages. Indeed, F4/80+Ly-6C+ inflammatory macrophages in the tumor microenvironment displayed high levels of these receptors. Whereas administration of the anti-TRP1 Ab alone reduced the frequency of these macrophages, the combination with a TLR agonist retained these cells in the tumor microenvironment. Thus, the addition of innate stimulatory compounds, such as TLR ligands, to tumor-specific Ab therapy could greatly enhance its efficacy in solid cancers via optimal exploitation of FcγRs.
Subject(s)
Antibodies/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Immunotherapy/methods , Interleukin-2/therapeutic use , Killer Cells, Natural/immunology , Macrophages/immunology , Melanoma/therapy , Receptors, IgG/metabolism , Animals , Antigens, Neoplasm/immunology , Disease Models, Animal , Female , Gene Expression Regulation, Neoplastic , Humans , Immunization , Male , Melanoma/immunology , Melanoma, Experimental , Membrane Glycoproteins/immunology , Mice , Mice, Inbred C57BL , Mice, Knockout , Oxidoreductases/immunology , Receptors, IgG/genetics , Toll-Like Receptors/agonistsABSTRACT
The naturally antibiotic-resistant bacterium Burkholderia pseudomallei is the causative agent of melioidosis, a disease with stubbornly high mortality and a complex, protracted treatment regimen. The worldwide incidence of melioidosis is likely grossly underreported, though it is known to be highly endemic in northern Australia and Southeast Asia. Bacterial disulfide bond (DSB) proteins catalyze the oxidative folding and isomerization of disulfide bonds in substrate proteins. In the present study, we demonstrate that B. pseudomallei membrane protein disulfide bond protein B (BpsDsbB) forms a functional redox relay with the previously characterized virulence mediator B. pseudomallei disulfide bond protein A (BpsDsbA). Genomic analysis of diverse B. pseudomallei clinical isolates demonstrated that dsbB is a highly conserved core gene. Critically, we show that DsbB is required for virulence in B. pseudomallei A panel of B. pseudomalleidsbB deletion strains (K96243, 576, MSHR2511, MSHR0305b, and MSHR5858) were phenotypically diverse according to the results of in vitro assays that assess hallmarks of virulence. Irrespective of their in vitro virulence phenotypes, two deletion strains were attenuated in a BALB/c mouse model of infection. A crystal structure of a DsbB-derived peptide complexed with BpsDsbA provides the first molecular characterization of their interaction. This work contributes to our broader understanding of DSB redox biology and will support the design of antimicrobial drugs active against this important family of bacterial virulence targets.
Subject(s)
Burkholderia pseudomallei/genetics , Burkholderia pseudomallei/pathogenicity , Melioidosis/pathology , Membrane Proteins/immunology , Mice, Inbred BALB C/immunology , Oxidoreductases/immunology , Virulence/genetics , Animals , Australia , Burkholderia pseudomallei/immunology , Disease Models, Animal , Melioidosis/genetics , Melioidosis/microbiology , Membrane Proteins/genetics , Membrane Proteins/metabolism , Mice , Oxidoreductases/genetics , Oxidoreductases/metabolism , Virulence/immunologyABSTRACT
Identification of pathogen-specific biomarkers present in patients' serum or urine samples can be a useful diagnostic approach. In efforts to discover Mycobacterium tuberculosis (Mtb) biomarkers we identified by mass spectroscopy a unique 21-mer Mtb peptide sequence (VVLGLTVPGGVELLPGVALPR) present in the urines of TB patients from Zimbabwe. This peptide has 100% sequence homology with the protein TBCG_03312 from the C strain of Mtb (a clinical isolate identified in New York, NY, USA) and 95% sequence homology with Mtb oxidoreductase (MRGA423_21210) from the clinical isolate MTB423 (identified in Kerala, India). Alignment of the genes coding for these proteins show an insertion point mutation relative to Rv3368c of the reference H37Rv strain, which generated a unique C-terminus with no sequence homology with any other described protein. Phylogenetic analysis utilizing public sequence data shows that the insertion mutation is apparently a rare event. However, sera from TB patients from distinct geographical areas of the world (Peru, Vietnam, and South Africa) contain antibodies that recognize a purified recombinant C-terminus of the protein, thus suggesting a wider distribution of isolates that produce this protein.
Subject(s)
Bacterial Proteins/urine , Mycobacterium tuberculosis/chemistry , Proteomics , Tuberculosis/urine , Amino Acid Sequence , Antibodies, Bacterial/blood , Bacterial Proteins/chemistry , Bacterial Proteins/genetics , Bacterial Proteins/immunology , Biomarkers/chemistry , Biomarkers/urine , Cluster Analysis , Humans , Mycobacterium tuberculosis/immunology , Oxidoreductases/chemistry , Oxidoreductases/genetics , Oxidoreductases/immunology , Oxidoreductases/urine , Peptide Fragments/chemistry , Peptide Fragments/genetics , Peptide Fragments/immunology , Peptide Fragments/urine , Tuberculosis/blood , Tuberculosis/diagnosisABSTRACT
Cancer is a global health issue that impairs the life quality of patients and origins thousands of deaths annually worldwide. Six-transmembrane epithelial antigen of the prostate (STEAP1) was identified to be overexpressed in several types of cancers, namely in prostate cancer (PCa). Considering its secondary structure, associated with its location in the cell membrane, has been suggested a role in intercellular communication between tumour cells. Taking into account its high specificity and overexpression in human cancers, STEAP1 is nowadays a promising candidate to be imposed as a therapeutic target. Several strategies have been developed during the last few years for targeting STEAP1, including antibody-drug conjugates, monoclonal antibodies (mAbs), DNA vaccines and small noncoding RNAs (ncRNAs). This review presents the current knowledge about STEAP1 protein expression in human tissues, its biochemical properties and targeting strategies with the purpose to evaluate its potential as therapeutic agent for cancer.